Sivelestat Sodium is a protease inhibitor primarily used in the treatment of acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Basic Information
English Name: Sivelestat Sodium
CAS Numbers: 201677-61-4
Molecular Weights: 528.51
Uses and Efficacy
Main Efficacy: Sivelestat Sodium is a competitive inhibitor of human neutrophil elastase (NE). By inhibiting lung inflammation mediated by white blood cells, it reduces lung inflammation and injury, improves respiratory function, and increases patient survival rates.
Therapeutic Areas: Primarily used for the treatment of severe lung diseases such as ARDS and ALI, which are often caused by infections, trauma, or other underlying conditions leading to inflammation and injury of the alveolar walls.
Clinical Application: Sivelestat Sodium is typically administered through intravenous injection and is commonly used in intensive care unit (ICU) settings.
Pharmacological Action
Mechanism of Action: Sivelestat Sodium highly specifically inhibits the activity of neutrophil elastase (NE), reducing the release of inflammatory factors and decreasing lung vascular permeability, thereby alleviating lung injury.
Anti-inflammatory and Lung Protective Mechanisms: Sivelestat Sodium exerts lung protective effects through various pathways, such as inhibiting signal transducer and activator of transcription (STAT) or tumor necrosis factor-α (TNF-α) pathways, as well as inhibiting NF-κB or high mobility group box 1 (HMGB1) inflammatory signaling pathways.
